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Previous studies have shown that intra-accumbens infusion of isoproterenol (ISO), a beta-
adrenoceptor-agonist, and phenylephrine (PE), an alpha-adrenoceptor-agonist, increase the
release of accumbal dopamine (DA). In the present study we analyzed whether the
ISO-induced release of DA is sensitive to pretreatment with the DA synthesis inhibitor
alpha-methyl-para-tyrosine (AMPT). Earlier studies have shown that the PE-induced release
of DA is derived from DA pools that are resistant to AMPT. In addition to PE, the alpha-
adrenoceptor-antagonist phentolamine (PA) was also found to increase accumbal DA
release. Therefore, we investigated whether similar to the DA-increasing effect of PE,
the DA increase induced by PA is resistant to AMPT. Pretreatment with AMPT prevented
the ISO-induced increase of accumbal DA. The accumbal DA increase after PA was not
reduced by the DA synthesis inhibitor, independently of the amount of DA released. These
results show that mesolimbic beta-, but not alpha-adrenoceptors, control the release of
accumbal newly-synthesized DA pools. The DA-increasing effects of PE have previously
been ascribed to stimulation of presynaptic receptors located on noradrenergic terminals,
whereas the DA-increasing effects of PA and ISO have been ascribed to an action of these
drugs at postsynaptic receptors on dopaminergic terminals. The fact that AMPT did not
affect the accumbal DA response to PE and PA, whereas it did prevent the accumbal
DA increase to ISO, supports our previously reported hypothesis that the noradrenergic
neurons of the nucleus accumbens containing presynaptic alpha-adrenoceptors impinge
upon the dopaminergic terminals in the nucleus accumbens containing postsynaptic
adrenoceptors of the alpha but not of the beta type. The putative therapeutic effects of
noradrenergic agents in the treatment of DA-related disorders are shortly discussed.
Keywords: noradrenaline-dopamine interactions, norepinephrine-dopamine interactions, alpha-adrenoceptors,
beta-adrenoceptors, phentolamine, isoproterenol, alpha-methyl-para-tyrosine, nucleus accumbens
INTRODUCTION
It has previously been demonstrated that the release of mesolim-
bic noradrenaline directs the release of mesolimbic dopamine
(DA) (in vitro studies: Nurse et al., 1984; Russell et al., 1993;
in vivo studies: Cools and Tuinstra, 2003; Verheij and Cools,
2008). Both, stimulation of accumbal beta-adrenoceptors by the
agonist isoproterenol (ISO), and inhibition of accumbal alpha-
adrenoceptors by the antagonist phentolamine (PA) have been
found to facilitate accumbal DA release (see Figure 1 in Tuinstra
and Cools, 2000; Verheij and Cools, 2009b). The DA increase
induced by ISO and PA have previously been ascribed to the
Abbreviations: AMPT, alpha-methyl-para-tyrosine; DA, dopamine; HR, high
responder(s) to novelty; ISO, isoproterenol; LR, low responder(s) to novelty;
PA, phentolamine; PE, phenylephrine; RES, reserpine.
binding of these agents at accumbal postsynaptic adrenocep-
tors located on dopaminergic nerve terminals (see Figure 1 in
Tuinstra and Cools, 2000; Verheij and Cools, 2009b). The mainly
postsynaptic action of these agents has been confirmed in more
recent studies showing that intra-accumbal administration of
various DA-increasing doses of either beta-adrenoceptor agonists
or alpha-adrenoceptor antagonists (Tuinstra and Cools, 2000;
Aono et al., 2013), did not affect accumbal noradrenaline levels
(Aono et al., 2007, 2013).
Interestingly, phenylephrine (PE), an alpha-adrenoceptor ago-
nist, has been found to act mainly at the presynaptic adreno-
ceptors of the nucleus accumbens (see Figure 1 in Tuinstra and
Cools, 2000; Verheij and Cools, 2009a). As expected, stimulation
of these presynaptic receptors by PE leads to a decreased accumbal
noradrenaline release (see Figure 1 in Aono et al., 2007) that
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in turn was found to result in an increase of the extracellular
levels of accumbal DA (see Figure 1 in Tuinstra and Cools, 2000;
Verheij and Cools, 2009a). Given that a decrease of accumbal
noradrenaline at the level of the DA-stimulating postsynaptic
beta-adrenoceptors would have resulted in a reduction of the
release of accumbal DA (see also: Mizoguchi et al., 2008), it has
previously been hypothesized that those noradrenergic neurons
that contain presynaptic alpha-adrenoceptors do not impinge
upon dopaminergic terminals that contain postsynaptic adreno-
ceptors of the beta type (see Figure 1 in Tuinstra and Cools,
2000). Accordingly, the finding that PE increased accumbal DA
release suggests that those noradrenergic neurons that contain
presynaptic alpha-adrenoceptors, impinge upon dopaminergic
terminals that contain postsynaptic adrenoceptors of the DA-
inhibitory alpha type (see Figure 1).
Accumbal DA can be released from two types of DA pools
(Ewing et al., 1983; Leviel et al., 1989; Verheij and Cools, 2007,
2009b). The first pool consists of newly-synthesized DA and
is sensitive to the DA synthesis inhibitor AMPT, whereas the
second pool consists of stored DA and is sensitive to the DA
vesicle depleter reserpine (RES; for review: Verheij and Cools,
2008). Microdialysis studies have shown that RES counteracts the
PA-, but not the ISO-induced accumbal DA release (Verheij and
Cools, 2009b). The first aim of the present study was to inves-
tigate whether AMPT may counteract the ISO-induced increase
of accumbal DA release (see Figures 1A,B). We have previously
shown that the PE-induced release of DA is derived from DA
pools that are insensitive to AMPT (Verheij and Cools, 2009a).
The second aim of the present study was to investigate whether the
accumbal DA increasing effects of the postsynaptic acting alpha-
agent PA are, in addition to the accumbal DA increasing effects
of the presynaptic acting alpha-agent PE, resistant to AMPT (see
Figures 1C,D). The third and final aim of the present study was to
provide additional evidence for the abovementioned hypothesis
that the presynaptic alpha-adrenoceptor of the nucleus accum-
bens are located on those noradrenergic nerve terminals that
impinge upon dopaminergic neurons containing postsynaptic
alpha-, but not beta-adrenoceptors (see Figures 1E,F).
The subjects used in the present study were low responder (LR)
and high responder (HR) to novelty rats (Piazza et al., 1989; Dellu
et al., 1996; Bevins et al., 1997; Cools and Gingras, 1998; Cools
and Tuinstra, 2003; Kabbaj, 2004; Verheij et al., 2009; Verheij and
Cools, 2011). Given that intra-accumbens administration of PA
has previously been found to result in a larger release of accumbal
DA in LR than in HR (Tuinstra and Cools, 2000), these rats
represent a useful tool to study whether the expected lack of effects
of AMPT in PA-treated rats is (in)dependent on the amount of DA
that is released.
MATERIALS AND METHODS
SUBJECTS
Adult male LR (n = 51) and HR (n = 51) rats of 180–220 g were
selected from the outbred strain of Nijmegen Wistar rats (see
Section Open-Field Selection Procedure). All rats were reared
and housed in Macrolon cages (42 × 26 × 15 cm; n = 3–4 per
cage) under a fixed 12/12 h light/dark cycle (lights on: 07.00 a.m.)
in a temperature-controlled room (21 ± 1.7◦C). Water and food
FIGURE 1 | Noradrenaline-(NA)-induced changes in accumbal DA
release. Postsynaptic beta-(β)-adrenoceptors stimulate (+) the release of
accumbal DA (A), whereas postsynaptic alpha-(α)-adrenoceptors inhibit (−)
the release of accumbal DA (C). The first aim of the study was to
investigate whether the postsynaptic acting beta-adrenoceptor agonist ISO
increases DA release from AMPT sensitive pools of DA (B). The second aim
of the study was to investigate whether the postsynaptic acting
alpha-adrenoceptor antagonist PA increases DA release from
AMPT-resistant pools of DA (D). Presynaptic alpha-(α)-adrenoceptors
regulate accumbal NA levels (E). The presynaptic acting alpha-adrenoceptor
agonist PE is known to reduce accumbal NA release (F). The third aim of
this study was to investigate whether the noradrenergic neurons that
contain presynaptic alpha-adrenoceptors impinge upon dopaminergic
neurons that contain postsynaptic alpha-, but not beta-adrenoceptors (F).
pellets (Ssniff, Soest, Germany) were available ad libitum, except
during the testing periods. All experiments were performed
in accordance with institutional, national and international
guidelines for animal care and welfare (see NRC 2003 guidelines).
Every effort was made to minimize the number of animals used
and their suffering.
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SELECTION OF LR AND HR TO NOVELTY
Rats were individually housed 3 days before the open-field selec-
tion procedure (Tuinstra and Cools, 2000; Verheij and Cools,
2007). Testing took place between 09.00 h and 17.00 h in a room
illuminated by white light of 170 Lux at the middle of the open-
field. Rats were placed on a black square table with no walls (160×
160 cm) for a period of 30 min. This open-field was 95 cm elevated
above the floor and surrounded by a white neutral background
(270 × 270 × 270 cm). As described by Cools et al. (1990),
behavior was recorded with a computerized tracking system. Both
ambulation and habituation time were used to select LR and HR.
Ambulation was defined as the overall distance (cm) traveled in
30 min. Habituation time was defined as the duration of the
period(s) that started as soon as the rat began to explore the
open-field and ended as soon as the locomotor activity stopped
for at least 90 s. Rats that habituated in less than 480 s and
walked less than 4800 cm in 30 min were labeled LR, whereas
rats that habituated after 840 s and walked more than 6000 cm
in 30 min were labeled HR (Tuinstra and Cools, 2000; Verheij
and Cools, 2007). Habituation time in addition to ambulation
was used as selection criterion, because traveled distance per
se is not always a reliable criterion (Cools et al., 1997; Saigusa
et al., 1999). Rats that did not fulfill the criteria were excluded
from this study. Efforts were made to use these rats in other
studies.
SURGERY
One day after the open-field selection procedure took place, LR
and HR were unilaterally implanted with a stainless steel guide
cannula (length: 5.5 mm, outer diameter: 0.65 mm, inner diame-
ter: 0.3 mm) directed to the right nucleus accumbens according
to previously described procedures (Tuinstra and Cools, 2000;
Verheij and Cools, 2007). Rats, anesthetized with pentobarbital
(60 mg/kg, i.p.), were placed in a stereotactic apparatus and
the following coordinates were used according to the atlas of
Paxinos and Watson (1986): anterior: +10.6 mm (relative to the
interaural line) and lateral: −1.5 mm (relative to the midline
suture). The guide cannula was lowered 5.5 mm relative to the
dura surface resulting in a vertical coordinate of +3.5 mm for
the cannula tip. Finally, the cannula was angled 10◦ laterally to
the right side. The rats were allowed to recover from surgery
for the next 7–10 days in Plexiglas dialysis cages (25 × 25 ×
35 cm) covered with sawdust on the floor. On 3 consecutive
days just prior to the start of the microdialysis experiment, each
rat was gently picked up in order to habituate to the procedure
assessed on the day when the concentration of accumbal DA
was measured. This handling procedure was repeated three times
per day.
MICRODIALYSIS
As previously described, a dialysis probe (type A-I-8-02, outer
diameter: 0.22 mm, 50,000-molecular-weight cut-off, Eicom,
Tokyo, Japan) was carefully inserted into the brain of a conscious
rat and secured to the guide cannula with a screw (Tuinstra
and Cools, 2000; Verheij and Cools, 2007). The tip of the
dialysis probe protruded 2 mm below the distal end of the
guide cannula into the nucleus accumbens. The probes had
an in vitro recovery of 10–12% for DA. The inlet and out-
let of the probe were connected to a swivel allowing the rat
to move undisturbed. Accumbal dialysates were analyzed for
DA (pg/40 µl) according to previously described procedures
(Tuinstra and Cools, 2000; Verheij and Cools, 2007). Briefly,
the probe was perfused at a rate of 2.0 µl/min with modified
Ringer solution (see Section Compounds) and the outflow was
collected in a sample loop and injected, once every 20 min,
into a high performance liquid chromatography (HPLC) sys-
tem. DA was separated from the remaining neurotransmitters
by means of reversed phase, ion-paring, liquid chromatogra-
phy and the concentration was measured using electrochemical
detection (ECD). The HPLC-ECD system (HTEC-500: Eicom,
Tokyo, Japan) was calibrated with a standard DA solution before
and after each experiment. The detection limit was 500 fg per
sample.
EFFECTS OF PHENTOLAMINE AND ISOPROTERENOL IN RATS TREATED
WITH ALPHA-METHYL-PARA-TYROSINE
At 4 h following probe insertion, the extracellular accumbal
concentration of DA is known to reach a stable baseline ±10%
(Saigusa et al., 1999; Tuinstra and Cools, 2000; De Leonibus
et al., 2006; Verheij and Cools, 2007; Verheij et al., 2008). As
soon as a stable baseline concentration of DA was reached, rats
were treated with AMPT according to previously described pro-
cedures (Saigusa et al., 1999). In short, 0.1 mM of AMPT or its
solvent was locally infused into the nucleus accumbens (40 min:
2µl/min) whereafter the rats were immediately exposed to a novel
cage (Saigusa et al., 1999; Verheij and Cools, 2011). This novel
cage was slightly larger than the home cage (new dimensions:
30 × 30 × 35 cm) and lacked sawdust on the floor (Saigusa
et al., 1999). It has previously been shown that after open-field
selection, HR and LR rats still differ in locomotor activity when
exposed to this new cage (see Saigusa et al., 1999; Verheij and
Cools, 2011). Rats were exposed to the novel cage, because this
environmental challenge strongly facilitates the AMPT-induced
DA decrease (Saigusa et al., 1999; Verheij and Cools, 2007). At
100 min after AMPT or its solvent (see also Section Compounds),
rats were subjected to a 40-min-lasting intra-accumbens infu-
sion of 0.001 mM of the beta-adrenoceptor-agonist ISO (solvent
AMPT: LR: n = 8, HR: n = 8; AMPT: LR: n = 8, HR: n = 8)
or 0.01 mM (2 µl/min) or the alpha-adrenoceptor-antagonist
PA (solvent AMPT: LR: n = 8, HR: n = 8; AMPT: LR: n = 9,
HR: n = 10). Infusion of modified Ringer solution (2 µl/min,
40 min) served as control for PA and ISO treatment (solvent
AMPT: LR: n = 9, HR: n = 9, AMPT: LR: n = 8, HR: n = 8).
All rats were randomly divided over the different treatment
groups.
The noradrenergic drugs were administered 100 min after
AMPT, because at this time AMPT still reduced the levels of
accumbal DA (see Section Results and Watanabe et al., 2005),
whereas the amount of accumbal noradrenaline has previously
been found to be returned to baseline levels (Verheij and Cools,
2009a). The dose of PA and ISO were chosen because these doses
have been shown to increase extracellular levels of DA in the
nucleus accumbens in a receptor-specific manner (Tuinstra and
Cools, 2000; Verheij and Cools, 2009b).
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HISTOLOGY
At the end of each experiment the rat was deeply anesthetized
with an overdose of sodium-pentobarbital (60 mg, i.p.) and
intracardially perfused with 60 ml 4% paraformaldehyde solution.
Vibratome sections (100 µm, Leica VT1000F; Leica, Rijswijk, The
Netherlands) were cut to determine the exact location of the
microdialysis probe.
COMPOUNDS
The following compounds and solutions were used (Tuinstra and
Cools, 2000; Verheij and Cools, 2009b): (1) ISO-hydrochloride
and PA-hydrochloride (Sigma, St Louis, USA); (2) dl-AMPT-
hydrochloride (Axel Kistner AB Fack, Göteborg, Sweden); and
(3) modified Ringer solution: 147 mM NaCl, 4 mM KCl, 1.1 mM
CaCl2.2H2O and 1.1 mM MgCl2.6H2O were dissolved in ultra
pure water (pH 6.0). The Ringer solution served as solvent for all
compounds.
STATISTICAL ANALYSIS
The drug-induced changes of accumbal DA were expressed as
a percentage of the concentration of DA that was measured in
the 20-min-lasting period just before these drugs were infused.
All data are expressed as the mean ± SEM. A three-way ANOVA
with the factors rat type, treatment, and time (for repeated
measures) was assessed followed by a post-hoc Student’s t-test
where appropriate. A probability level of p < 0.05 was taken
as significant. SPSS for Windows (Release 12) was used to
statistically analyze the data.
RESULTS
OPEN-FIELD SELECTION PROCEDURE
The open-field selection procedure revealed 25% LR and 26%
HR. The average distance traveled in 30 min (±SEM) was 3425
± 123.6 cm and 8273± 233.0 cm in LR and HR, respectively. The
average habituation time (±SEM) was 353 ± 20.8 s in LR and
1322± 58.2 s in HR.
HISTOLOGY
Following histological verification, 1 LR treated with the solvent
of AMPT and PA had to be excluded from the analysis due to
an incorrect placement of the microdialysis probe (number of
rats included in data analysis: 51− 1 = 50 LR and 51− 0 = 51
HR). The coronal region of the nucleus accumbens in which all
correctly placed microdialysis probe tracks were located is shown
in Figure 2.
BASAL LEVELS OF DOPAMINE
Baseline extracellular levels of accumbal DA were 3.8 ± 0.15
pg/sample in LR and 4.40 pg ± 0.31 pg/sample in HR (rat type
effect: F(1,99) = 3.219, p = 0.076).
EFFECTS OF ALPHA-METHYL-PARA-TYROSINE
As previously reported (Saigusa et al., 1999; Verheij and Cools,
2007; Verheij et al., 2008), accumbal DA levels increased less in
novelty-challenged LR than in novelty-challenged HR (Figure 3:
rat type × time effect: F(7,336) = 4.304, p < 0.001). The novelty-
induced increase of DA lasted 60 min in LR (Figure 3A: one
FIGURE 2 | (A) Example of three unilateral microdialysis probe tracks
located in the right nucleus accumbens. The probe protrudes 2 mm below
the distal end of the guide cannula. (B–D) Schematic illustration of coronal
brain sections containing the nucleus accumbens. The brain region in
which correctly placed probes were found is indicated as a gray oval. IA
corresponds to the distance (mm) from the interaural line according to
Paxinos and Watson (1986), NAC = nucleus accumbens, CPU = caudate
putamen, CC = corpus callosum.
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FIGURE 3 | Effects of intra-accumbens infusion of AMPT (0.1 mM, 2
µl/min, 40 min) on the DA levels in novelty-challenged low responders
(LR) (A) and novelty-challenged high responders (HR) (B). Values are
accumbal DA levels expressed as percentage of the average of the three
baseline samples collected before AMPT was infused (basal samples b1-b3).
Both PA and ISO were infused 100 min after AMPT was given. This infusion
point was labeled basal sample b4. It is important to note that the DA levels
of the control animals were returned to baseline when PA and ISO were
infused, whereas the DA levels in AMPT-treated animals were still reduced.
Data are expressed as mean percentage ± SEM. The solid horizontal line
represents the infusion time of AMPT. # Significant DA increase after novelty
(DA levels were compared to baseline levels using one sample t-tests). *
Significant DA decrease after AMPT (DA levels of AMPT-treated rats were
compared to DA levels of control (Ringer) animals using Student’s t-tests).
sample t-test: t = 20–60 min: p < 0.05 and t = 80–100 min: ns)
and 80 min in HR (Figure 3B: one sample t-test: t = 20–80 min:
p < 0.05 and t = 100 min: ns). AMPT strongly decreased the
extracellular levels of accumbal DA in these rats (Figure 3: treat-
ment × time effect (t = 0–100 min): F(7,679) = 33.437, p < 0.001,
rat type × treatment × time effect: F(7,679) = 6.705, p < 0.001).
AMPT did not reduce the increase of accumbal DA in the 60-
min-lasting-period that DA increased in novelty-challenged LR
(Figure 3A: Student’s t-test: t = 20–60 min: ns), whereas it
reduced the DA increase during this period in novelty-challenged
HR (Figure 3B: Student’s t-test: t = 20–60 min: p < 0.05).
These results confirm our previous findings that the relative
large novelty-induced increase of accumbal DA in HR is derived
from AMPT-sensitive pools, whereas the relative small novelty-
induced increase of accumbal DA in LR is derived from AMPT-
resistant pools (Saigusa et al., 1999; Verheij and Cools, 2007).
For the present study, it is important to note that AMPT
decreased accumbal DA levels at 100 min after AMPT in both
LR and HR rats (Figure 3: Student’s t-test: t = 100 min: LR:
p < 0.05 and HR: p < 0.05; rat type × treatment effect
(t = 100 min): ns).
RATS ARE AT REST DURING THE INFUSION OF ISOPROTERENOL AND
PHENTOLAMINE
As mentioned above, the DA levels of the control rats did not
differ anymore from the baseline levels of DA at t = 100 min
after novelty (Figure 3: one sample t-test at t = 100 min: LR: ns,
HR: ns). In addition, the accumbal DA levels of these rats did not
change over time during the period after t = 100 min (Figures 4, 6:
time effect: LR: ns, HR: ns). These data demonstrate that both LR
and HR were not anymore challenged at the time of the infusion
of ISO or PA.
EFFECTS OF ISOPROTERENOL IN
ALPHA-METHYL-PARA-TYROSINE-TREATED RATS
The dose of 0.001 mM of the beta-adrenoceptor-agonist ISO
equally increased accumbal DA levels in non-challenged LR and
non-challenged HR that were treated with the solvent of AMPT
(Figure 4: treatment× time effect: F(5,150) = 12.477, p< 0.001; rat
type× treatment (× time) effect: ns). AMPT equally reduced this
ISO-induced DA increase in both type of rats (Figure 5: treatment
× time effect: F(5,140) = 9.045, p < 0.001; rat type × treatment
(× time) effect: ns). ISO did not increase anymore accumbal DA
levels in either AMPT-treated LR or AMPT-treated HR (Figure 5:
treatment (× time) effect: ns).
EFFECTS OF PHENTOLAMINE IN
ALPHA-METHYL-PARA-TYROSINE-TREATED RATS
The dose of 0.01 mM of the alpha-adrenoceptor-antagonist PA
increased accumbal DA levels in both LR and HR that were treated
with the solvent of AMPT (Figure 6). The PA-induced increase
of accumbal DA was larger in non-challenged LR than in non-
challenged HR (Figure 6: rat type × treatment × time effect:
F(5,150) = 8.911, p < 0.006; LR (Figure 6A): treatment × time
effect: F(5,75) = 21.436, p < 0.001; HR (Figure 6B): treatment ×
time effect: F(5,75) = 4.929, p = 0.001). As in AMPT solvent-treated
rats, PA increased accumbal DA levels more strongly in AMPT-
treated LR than in AMPT-treated HR (Figure 7: rat type × treat-
ment × time effect: F(5,155) = 3.474, p = 0.005; LR (Figure 7A):
treatment × time effect: F(5,75) = 20.643, p < 0.001; HR
(Figure 7B): treatment × time effect: F(5,80) = 4.842, p = 0.001).
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FIGURE 4 | Effects of the intra-accumbens infusion of the
beta-adrenoceptor-agonist ISO (0.001 mM, 2 µl/min, 40 min) on the
extracellular concentration of DA in the nucleus accumbens of LR (A)
and HR (B) under non-novelty-challenged conditions. All rats were
treated with the solvent of AMPT. Values are accumbal DA levels
expressed as percentage of the sample collected just before ISO was
infused (basal sample b4 of Figure 3). Data are expressed as mean
percentage ± SEM. The solid horizontal line represents the infusion time
of ISO. * Significant DA increase after ISO (Student’s
t-test).
FIGURE 5 | Effects of AMPT (0.1 mM, 2 µl/min, 40 min) on the
ISO-induced increase of the extracellular concentration of DA in the
nucleus accumbens of non-challenged LR (A) and non-challenged HR (B).
Values are accumbal DA levels expressed as percentage of the sample
collected just before ISO was infused (basal sample b4 of Figure 3). Data are
expressed as mean percentage ± SEM. The solid horizontal line represents
the infusion time of ISO. * AMPT-induced reduction of the ISO-induced DA
increase (Student’s t- test).
In fact, the DA-increasing effects of PA in AMPT-treated rats were
not different from the DA-increasing effects of PA in rats that
were treated with AMPT solvent (Figure 7: treatment (× time)
effect: ns).
DISCUSSION
We have previously demonstrated that binding of the beta-
adrenoceptor agonist ISO to the postsynaptic beta-adrenoceptors
of the nucleus accumbens increases accumbal DA release
(Figure 1). The first aim of the present study was to investigate
whether this ISO-induced DA release is derived from AMPT-
sensitive pools of DA (see also Figure 1). In addition to
the presynaptic acting alpha-adrenoceptor-agonist PE, the
postsynaptic acting alpha-adrenoceptor-antagonist PA was also
found to increase accumbal DA release (Figure 1). The second
aim of this study was to investigate whether the DA-increasing
effects of PA were like the DA-increasing effects of PE resistant to
AMPT (see also Figure 1).
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FIGURE 6 | Effects of the intra-accumbens infusion of the
alpha-adrenoceptor-antagonist PA (0.01 mM, 2 µl/min, 40 min) on
the extracellular concentration of DA in the nucleus accumbens
of LR (A) and HR (B) under non-novelty-challenged conditions. All
rats were treated with the solvent of AMPT. Values are accumbal DA
levels expressed as percentage of the sample collected just before
PA was infused (basal sample b4 of Figure 3). Data are expressed
as mean percentage ± SEM. The solid horizontal line represents the
infusion time of PA. * Significant DA increase after PA (Student’s
t-test).
FIGURE 7 | Effects of AMPT (0.1 mM, 2 µl/min, 40 min) on the
PA-induced increase of the extracellular concentration of DA in the
nucleus accumbens of the non-challenged LR (A) and non-challenged HR
(B). Values are accumbal DA levels expressed as percentage of the sample
collected just before PA was infused (basal sample b4 of Figure 3). Data are
expressed as mean percentage ± SEM. The solid horizontal line represents
the infusion time of PA. There was no AMPT-induced reduction of the
PA-induced DA increase (Student’s t-test).
DUAL ROLE OF NORADRENALINE IN MEDIATING DOPAMINE RELEASE
As expected, intra-accumbens infusion of PA and ISO
increased accumbal DA levels in rats treated with the
solvent of AMPT (Figures 4, 6). This accumbal DA increase
may very well explain the previously reported increase in
locomotor activity observed following the inhibition and
stimulation of accumbal alpha- and beta-adrenoceptors,
respectively (Verheij et al., accepted). It has been demonstrated
previously that the DA increase following intra-accumbens
administration of PA and ISO are dose-dependent and
receptor-specific (Tuinstra and Cools, 2000). The present
study also confirms the previously reported finding that
the effects of ISO do not differ between non-challenged LR
and HR (Tuinstra and Cools, 2000), whereas the effects of
PA are larger in the former than in the latter (Tuinstra and
Cools, 2000). These results have previously been ascribed
to individual differences in the noradrenergic activity at
accumbal postsynaptic alpha-, but not beta-adrenoceptors in
non-challenged LR and HR rats (for details: Tuinstra and Cools,
2000).
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FIGURE 8 | Summary of the findings of the present and previous
studies. Changes in arrow weight represent changes in noradrenaline (NA)
and/or DA release. (A–B) An increase of NA at the level of the postsynaptic
beta (β)-, but not alpha (α)-adrenoceptors of the nucleus accumbens
stimulates (+) accumbal DA release from AMPT-sensitive pools of
newly-synthesized DA (present study) that are resistant to RES (see: Verheij
and Cools, 2009b). (C–D) An increase of NA at the level of the postsynaptic
alpha-, but not beta-adrenoceptors of the nucleus accumbens inhibits (–)
accumbal DA release from RES sensitive vesicular DA pools (see: Verheij and
Cools, 2009b) that are resistant to AMPT (present study). (E–F) The
presynaptic alpha-adrenoceptors of the nucleus accumbens (see: Tuinstra
and Cools, 2000; Verheij and Cools, 2009a) are known to inhibit (–) accumbal
NA release (see: Aono et al., 2007). The present study indicates that this
reduction of accumbal NA leads to an increase of accumbal DA (see also:
Tuinstra and Cools, 2000; Verheij and Cools, 2009a) because the
noradrenergic neurons containing presynaptic alpha-adrenoceptors impinge
upon dopaminergic neurons equipped with postsynaptic alpha-, but not
beta-receptors.
EFFECTS OF ALPHA-METHYL-PARA-TYROSINE ON THE DOPAMINE
RELEASE AFTER ISOPROTERENOL OR PHENTOLAMINE
The finding that AMPT completely prevented the ISO-induced
increase of accumbal DA levels in both LR (Figure 5A) and
HR (Figure 5B) shows that ISO increases DA release from
AMPT-sensitive DA pools. Importantly, the local infusion of
AMPT completely depleted the newly-synthesized pools of DA
in both rat types (Figure 5). Despite the fact that the newly-
synthesized pools of DA were shown to be completely empty
(Figure 5), the local infusion of PA led to an increase of accumbal
DA levels in both AMPT-treated LR (Figure 7A) and AMPT-
treated HR (Figure 7B). In fact, the PA-induced DA release in
these AMPT-treated rats did not differ from the PA-induced
DA release in rats treated with AMPT-solvent (Figure 7). The
finding that not only the small PA-induced DA increase in HR,
but also the large PA-induced DA increase in LR is insensitive
to AMPT (Figure 7) illustrates that the PA-mediated DA release
is independent on AMPT-sensitive pools of DA even when the
release of DA is high.
CONCLUSIONS
It has recently been shown that the increase of accumbal DA
induced by ISO is due to the simultaneous stimulation of
accumbal beta-1 and beta-2 receptors (Aono et al., 2013). The
present finding that the ISO-induced increase of accumbal DA
is sensitive to AMPT (see above) shows that the postsynaptic
beta1/2-adrenoceptors of the nucleus accumbens mediate (i.e.,
stimulate) accumbal DA release from newly-synthesized pools
of DA (Figure 8). In a previous study we have shown that the
ISO-induced increase of accumbal DA release is not sensitive
to reserpine (RES; Verheij and Cools, 2009b). This indicates
that the AMPT-sensitive and newly-synthesized DA pools that
are controlled by postsynaptic beta1/2-adrenoceptors are not
vesicular (Figure 8). The PA-induced increase of accumbal DA is
due to inhibition of alpha-1 but not alpha-2 receptors (Ihalainen
et al., 2004; Saigusa et al., 2012). In contrast to the ISO-induced
increase of accumbal DA, the PA-induced increase of accumbal
DA was found to be sensitive to RES (Verheij and Cools, 2009b)
demonstrating that the postsynaptic alpha-1-adrenoceptors of the
nucleus accumbens mediate (i.e., inhibit) accumbal DA release
from vesicular pools of DA (Figure 8). The present finding that
the PA-induced increase of accumbal DA release is not sensitive to
AMPT (see above) indicates that the RES-sensitive and vesicular
DA pools controlled by alpha-1-adrenoceptors do not contain
newly synthesized DA (Figure 8). The fact that the DA increase
mediated by postsynaptic beta-1/2-adrenoceptors is sensitive to
AMPT (present study), whereas the DA increase mediated by
presynaptic alpha-1-adrenoceptors is not (Verheij and Cools,
2009a), indicates that the presynaptic alpha-1-adrenoceptors of
the nucleus accumbens are not located on the noradrenergic
nerve-terminals that impinge upon dopaminergic neurons
expressing postsynaptic beta-1/2-receptors (Figure 8). The
finding that both the DA increase mediated by presynaptic alpha-
1-adrenoceptors (Verheij and Cools, 2009a) and the DA increase
mediated by postsynaptic alpha-1-adrenoceptors (present
study) are insensitive to AMPT confirms our hypothesis (see
Section Introduction) that presynaptic alpha-1-adrenoceptors in
Frontiers in Cellular Neuroscience www.frontiersin.org August 2014 | Volume 8 | Article 243 | 8
Meyer et al. Noradrenaline-induced release of newly-synthesized dopamine
the nucleus accumbens are located on those noradrenergic nerve-
terminals that impinge upon dopaminergic neurons equipped
with post-synaptic alpha-1-receptors (Figure 8).
Our study underlines the view that mesolimbic noradrenaline
fulfills many functions that are, up to now, primarily ascribed
to mesolimbic DA (Cools and Tuinstra, 2003). Indeed, both
accumbal DA and accumbal noradrenaline were found not only
to regulate locomotor activity (Pijnenburg et al., 1975; Costall
et al., 1976; Cools et al., 1987; Ikeda et al., 2007; Verheij et al.,
accepted), sensorimotor gating (Alsene et al., 2010, 2011) and
anxiety (Roozendaal and Cools, 1994; Kochenborger et al., 2012),
but also more complex behaviors that are depending on learning
and memory (Tuinstra et al., 2000, 2002; Kerfoot et al., 2008;
Kerfoot and Williams, 2011) processes (for review: Verheij and
Cools, 2008).
IMPACT
Changes in accumbal DA are generally accepted to play a key role
in addiction (Koob, 1992; Everitt and Robbins, 2005), schizophre-
nia (Gray et al., 1991; Gray, 1995; Carlsson et al., 2001; Kuepper
et al., 2012) and Parkinson’s disease (Hornykiewicz, 1998; van
Oosten et al., 2005). This explains why dopaminergic manipu-
lations are widely used to treat these disorders. However, serious
side effects of drugs that directly act at the dopaminergic receptors
of the brain have been reported (Platt et al., 2002; Serretti et al.,
2004; Ahlskog, 2011; Stowe et al., 2011; Meltzer, 2013). Partial
DA agonists, however, are predicted to lead to fewer side effects
because these drugs do not result in maximum stimulation of DA
receptors (Jenner, 2002; Platt et al., 2002; Ohlsen and Pilowsky,
2005). Growing evidence indicates that moderate changes of
endogenous DA levels in only a limited number of dopaminergic
neurons, or at a limited number of dopaminergic receptors, may
represent very powerful tools to treat dopaminergic diseases with-
out producing severe side effects (Withers et al., 1995; Dixon et al.,
1999; Müller, 2001; Mailman and Murthy, 2010; Diana, 2011).
The fact that alpha- and beta-adrenoceptors control the release
of DA from different types of dopaminergic pools (Figure 8,
see also: Verheij and Cools, 2008, 2009b), which are in turn
believed to control their own class of dopaminergic receptors (for
review: Verheij and Cools, 2008), indicates that by choosing the
appropriate noradrenergic treatment it may very well be possible
to change the release of endogenous DA only from those pools
that are involved in the therapeutic effects of DA, but not from
the pools that induce DA-related side effects.
Whether an alpha- or beta-adrenergic agent has therapeutic
potential depends on the disease to be treated. We have previ-
ously hypothesized that alpha-adrenoceptor-induced changes in
vesicular DA release may be beneficial in the treatment of cocaine
addiction and Parkinson’s disease, whereas beta-adrenoceptor-
induced changes in the release of newly-synthesized DA may
be beneficial in the treatment of amphetamine addiction and
the positive symptoms of schizophrenia (for references see:
Verheij and Cools, 2008). Indeed, it has recently been found
that alpha-adrenoceptor antagonists reduce both the behavioral
and accumbal DA response to cocaine (Mitrano et al., 2012),
presumably by acting on the pre-synaptic alpha-1-adreneceptors
of the nucleus accumbens (Verheij et al., 2013). In the future,
additional animal studies will be needed to further investigate
the beneficial effects of noradrenergic drugs as treatment for DA-
related disorders.
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